News Releases | Portage Biotech

Year

12 Apr '24

Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives

-Adenosine clinical development paused WESTPORT, Conn. , April 12, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported that it is expanding its

26 Mar '24

Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares

Company generated approximately $2.8M of non-dilutive funding to extend cash runway WESTPORT, Conn. , March 26, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination,

28 Feb '24

Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update

Company focused on adenosine platform clinical development WESTPORT, Conn. , Feb. 28, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in

04 Jan '24

Portage Biotech Reports Business and Strategic Update

Prioritize the adenosine clinical candidates iNKT clinical development paused to focus resources Company will evaluate range of strategic options WESTPORT, Conn. , Jan. 04, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel